{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:19Z","timestamp":1794047539333,"version":"4.8.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2018.05.119","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T13:05:47Z","timestamp":1528117547000},"page":"5544-5550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Vaccine-preventable diseases, vaccines and Guillain-Barre\u2019 syndrome"],"prefix":"10.1016","volume":"37","author":[{"given":"Nicola","family":"Principi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.119_b0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2018.05.119_b0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000339248","article-title":"Guillain-Barr\u00e9 syndrome incidence in a large United States cohort (2000\u20132009)","volume":"39","author":"Shui","year":"2012","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2018.05.119_b0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000184748","article-title":"The epidemiology of Guillain-Barr\u00e9 syndrome worldwide. A systematic literature review","volume":"32","author":"McGrogan","year":"2009","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2018.05.119_b0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jneuroim.2003.11.017","article-title":"Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination","volume":"148","author":"Nishimoto","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.vaccine.2018.05.119_b0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jocn.2008.08.033","article-title":"Guillain-Barr\u00e9 syndrome: an update","volume":"16","author":"Vucic","year":"2009","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.vaccine.2018.05.119_b0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/bmj.a671","article-title":"Guillain-Barr\u00e9 syndrome","volume":"337","author":"Winer","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.05.119_b0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF00296569","article-title":"Acute severe combined demyelination","volume":"8","author":"Amit","year":"1992","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.vaccine.2018.05.119_b0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1034\/j.1600-0404.2002.00099.x","article-title":"Autonomic function in demyelinating and axonal subtypes of Guillain-Barr\u00e9 syndrome","volume":"105","author":"Asahina","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.vaccine.2018.05.119_b0045","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3329\/jhpn.v28i6.6602","article-title":"Quantifying the association between Campylobacter infection and GuillainBarr\u00e9 syndrome: a systematic review","volume":"28","author":"Poropatich","year":"2010","journal-title":"J Health Popul Nutr"},{"key":"10.1016\/j.vaccine.2018.05.119_b0050","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1212\/WNL.56.6.758","article-title":"Preceding infections, immune factors, and outcome in Guillain-Barr\u00e9 syndrome","volume":"56","author":"Hadden","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2018.05.119_b0055","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","article-title":"The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study","volume":"51","author":"Jacobs","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2018.05.119_b0060","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.05.119_b0065","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3109\/00207454.2015.1033621","article-title":"Guillain-Barr\u00e9 syndrome following chickenpox: a case series","volume":"126","author":"Tatarelli","year":"2016","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.vaccine.2018.05.119_b0070","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s10072-014-1841-2","article-title":"Guillain-Barr\u00e9 syndrome following measles infection: case report and review of the literature","volume":"35","author":"Filia","year":"2014","journal-title":"Neurol Sci"},{"key":"10.1016\/j.vaccine.2018.05.119_b0075","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/123.10.2171","article-title":"Haemophilus influenzae infection and Guillain-Barr\u00e9 syndrome","volume":"123","author":"Mori","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.vaccine.2018.05.119_b0080","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1473-3099(10)70140-7","article-title":"Guillain-Barre syndrome after exposure to influenza virus","volume":"10","author":"Lehmann","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.119_b0085","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/aje\/kwn310","article-title":"Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza like illness using the United Kingdom general practice research database","volume":"169","author":"Stowe","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.05.119_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000344","article-title":"Guillain-Barre syndrome and preceding infection with Campylobacter, influenza and Epstein-Barr virus in the general practice research database","volume":"2","author":"Tam","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.05.119_b0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1086\/594124","article-title":"Guillain-Barr\u00e9 syndrome and influenza virus infection","volume":"48","author":"Sivadon-Tardy","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.119_b0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10654-015-0047-0","article-title":"Risk of Guillain-Barr\u00e9 syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study","volume":"3","author":"Ghaderi","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.05.119_b0105","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(11)61665-6","article-title":"Guillain-Barre syndrome and H1N1 influenza vaccine in UK children","volume":"378","author":"Verity","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.119_b0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00005792-196905000-00001","article-title":"The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis","volume":"48","author":"Asbury","year":"1969","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2018.05.119_b0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1085-9489.2005.0010207.x","article-title":"Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"10","author":"Allen","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.vaccine.2018.05.119_b0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0165-5728(96)00059-8","article-title":"Association of anti-GM2 antibodies in Guillain-Barr\u00e9 syndrome with acute cytomegalovirus infection","volume":"68","author":"Irie","year":"1996","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.vaccine.2018.05.119_b0125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.880180407","article-title":"Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection","volume":"18","author":"Kusunoki","year":"1995","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.vaccine.2018.05.119_b0130","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.1128\/IAI.00967-06","article-title":"Ganglioside molecular mimicry and its pathological roles in Guillain-Barr\u00e9 syndrome and related diseases","volume":"74","author":"Yu","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.05.119_b0135","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.1012","article-title":"Animal model of axonal Guillain-Barr\u00e9 syndrome induced by sensitization with GM1 ganglioside","volume":"49","author":"Yuki","year":"2001","journal-title":"Ann Neurol"},{"issue":"12\u201320","key":"10.1016\/j.vaccine.2018.05.119_b0140","first-page":"51","article-title":"Experimental axonopathy induced by immunization with Campylobacter jejuni lipopolysaccharide from a patient with Guillain-Barr\u00e9 syndrome","volume":"174","author":"Caporale","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.vaccine.2018.05.119_b0145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jns.2008.05.006","article-title":"Validation of a rabbit model of neuropathy induced by immunization with gangliosides","volume":"272","author":"Moyano","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.vaccine.2018.05.119_b0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/jnnp-2011-300309","article-title":"Antiganglioside antibodies are associated with axonal Guillain-Barr\u00e9 syndrome: a Japanese-Italian collaborative study","volume":"83","author":"Sekiguchi","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.vaccine.2018.05.119_b0155","first-page":"1180","article-title":"Axonal Guillain-Barr\u00e9 syndrome: concepts and controversies","volume":"12","author":"Kuwabara","year":"2013","journal-title":"LancetNeurol"},{"key":"10.1016\/j.vaccine.2018.05.119_b0160","first-page":"178","article-title":"Guillain-Barr\u00e9 syndrome associated with immunization against rabies: epidemiological aspects","volume":"49","author":"Lopez","year":"1971","journal-title":"ResPubl Assoc Res Nerv Ment Dis"},{"key":"10.1016\/j.vaccine.2018.05.119_b0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0022-510X(87)90099-2","article-title":"Unusual features of the Guillain-Barre syndrome after rabies vaccine prepared in suckling mouse brain","volume":"81","author":"Cabrera","year":"1987","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.vaccine.2018.05.119_b0170","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and Guillain-Barr\u00e9 syndrome","volume":"32","author":"Haber","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2018.05.119_b0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0140-6736(05)78156-3","article-title":"Association between oral poliovaccine and Guillain-Barr\u00e9 syndrome?","volume":"351","author":"Salisbury","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.119_b0180","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2105\/AJPH.87.12.2045","article-title":"The risk of Guillain-Barr\u00e9 syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States","volume":"87","author":"Tuttle","year":"1997","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2018.05.119_b0185","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0002-9343(76)90762-2","article-title":"Guillain-Barr\u00e9 syndrome following administration of live measles vaccine","volume":"60","author":"Grose","year":"1976","journal-title":"Am J Med"},{"key":"10.1016\/j.vaccine.2018.05.119_b0190","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(94)90917-2","article-title":"Guillain-Barr\u00e9 syndrome after measles, mumps, and rubella vaccine","volume":"343","author":"Morris","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.119_b0195","first-page":"1636","article-title":"Polyradikulit I anslutningen till vaccination mot morbilli, parotit och rubella","volume":"81","author":"Jonse","year":"1984","journal-title":"L\u00e4kartidningen"},{"key":"10.1016\/j.vaccine.2018.05.119_b0200","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/bmj.295.6608.1264","article-title":"Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella","volume":"295","author":"B\u00f6ttiger","year":"1987","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.05.119_b0205","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/0264-410X(90)90245-H","article-title":"Measles mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects","volume":"8","author":"Fescharek","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.119_b0210","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0140-6736(95)90302-X","article-title":"Gait disturbances after measles, mumps, and rubella vaccine","volume":"345","author":"Plesner","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.119_b0215","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.312.7044.1475d","article-title":"Vaccines and Guillain-Barr\u00e9 syndrome","volume":"312","author":"Hughes","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.05.119_b0220","series-title":"Adverse events associated with childhood vaccines: evidence bearing on causality. Measles and mumps vaccines","author":"Institute of Medicine","year":"2011"},{"key":"10.1016\/j.vaccine.2018.05.119_b0225","unstructured":"Merck Sharp & Dohme Limited. MMRVAXPRO. https:\/\/www.medicines.org.uk\/emc\/product\/6307 [accessed 19.12.17]."},{"key":"10.1016\/j.vaccine.2018.05.119_b0230","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1067\/mpd.2001.111165","article-title":"Risk of Guillain-Barr\u00e9 syndrome after measles-mumps-rubella vaccination","volume":"138","author":"Patja","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2018.05.119_b0235","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1016\/j.vaccine.2008.07.014","article-title":"Relationship between occurrence of Guillain-Barre syndrome and mass campaign of measles and rubella immunization in Iranian 5\u201314 years old children","volume":"26","author":"Esteghamati","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.119_b0240","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(96)07408-9","article-title":"Measles vaccination and Guillain-Barr\u00e9 syndrome","volume":"349","author":"da Silveira","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.119_b0245","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstr\u00f6m","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.05.119_b0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pvr.2017.03.001","volume":"3","author":"Skufca","year":"2017","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2018.05.119_b0255","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. Vaccins anti- HPV et risque de maladies auto-immunes: \u00e9tude pharmaco-\u00e9pid\u00e9miologique, 2015. http:\/\/ansm.sante.fr\/searchengine\/general_search?SearchText=HPV+vaccine+and+GBS&ok=Valider [accessed 19.12.17]."},{"key":"10.1016\/j.vaccine.2018.05.119_b0260","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France","volume":"35","author":"Miranda","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.119_b0265","unstructured":"World Health Organization. Safety of HPV Vaccines. http:\/\/www.who.int\/vaccine_safety\/committee\/topics\/hpv\/Dec_2015\/en\/ [accessed 19.12.17]."},{"key":"10.1016\/j.vaccine.2018.05.119_b0270","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papilloma virus vaccine: A self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.119_b0275","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2018.05.119_b0280","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/pds.3554","article-title":"Pooled analysis of large and long-term safety data from the human papillomavirus-16\/18-AS04-adjuvanted vaccine clinical trial programme","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2018.05.119_b0285","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"issue":"RR-05","key":"10.1016\/j.vaccine.2018.05.119_b0290","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2018.05.119_b0295","first-page":"393","article-title":"Meeting of the global advisory committee on vaccine safety, 7\u20138 June 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Weekly Epidemiol Record"},{"key":"10.1016\/j.vaccine.2018.05.119_b0300","first-page":"1023","article-title":"Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine\u2013United States, June-July 2005","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.05.119_b0305","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.vaccine.2009.10.050","article-title":"MCV vaccination in the presence of vaccine-associated Guillain-Barr\u00e9 Syndrome risk: a decision analysis approach","volume":"28","author":"Cho","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.119_b0310","first-page":"364","article-title":"Update: Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine\u2014United States, October 2005\u2013 February 2006","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.05.119_b0315","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/pds.3321","article-title":"Risk of Guillain-Barr\u00e9 syndrome after meningococcal conjugate vaccination","volume":"21","author":"Velentgas","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2018.05.119_b0320","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/pds.3353","article-title":"No risk of Guillain-Barr\u00e9 syndrome found after meningococcal conjugate vaccination in two large cohort studies","volume":"21","author":"Yih","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"RR-2","key":"10.1016\/j.vaccine.2018.05.119_b0325","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2018.05.119_b0330","unstructured":"Sanofi Pasteur. Menactra. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM131170.pdf [accessed 19.12.17]."},{"key":"10.1016\/j.vaccine.2018.05.119_b0335","unstructured":"Food and Drug Administration. Menveo. fda.gov\/BiologicsBlood Vaccines\/Vaccines\/ApprovedProducts\/ucm201342.htm [accessed 19.12.17]."},{"key":"10.1016\/j.vaccine.2018.05.119_b0340","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/oxfordjournals.aje.a113809","article-title":"An epidemiologic and clinical-evaluation of Guillain-Barre-syndrome reported in association with the administration of swine influenza vaccines","volume":"119","author":"Langmuir","year":"1984","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.05.119_b0345","series-title":"Immunization safety review: influenza vaccines and neurological complications","author":"Institute of Medicine","year":"2003"},{"key":"10.1016\/j.vaccine.2018.05.119_b0350","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barre syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.119_b0355","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.amepre.2010.05.022","article-title":"Evaluation of Guillain-Barre syndrome among recipients of influenza vaccine in 2000 and 2001","volume":"39","author":"Burwen","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2018.05.119_b0360","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/aje\/kwp345","article-title":"Near real-time surveillance for influenza vaccine safety: proof-of-concept in the vaccine safety datalink project","volume":"171","author":"Greene","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"473\u2013474","key":"10.1016\/j.vaccine.2018.05.119_b0365","first-page":"20","article-title":"Guillain-Barre syndrome\u2014reply","volume":"367","author":"Hughes","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.119_b0370","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.166.20.2217","article-title":"Guillain-Barre syndrome after influenza vaccination in adults\u2014a population-based study","volume":"166","author":"Juurlink","year":"2006","journal-title":"Arch Int Med"},{"key":"10.1016\/j.vaccine.2018.05.119_b0375","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1982.03330060038030","article-title":"Guillain-Barr\u00e8 syndrome in the United States, 1979\u20131980 and 1980\u20131981\u2014lack of an association with influenza vaccination","volume":"248","author":"Kaplan","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.05.119_b0380","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","article-title":"The Guillain-Barre syndrome and the 1993 and 1993\u20131994 influenza vaccines","volume":"339","author":"Lasky","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.05.119_b0385","unstructured":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59(RR-8): p. 1\u201361."},{"key":"10.1016\/j.vaccine.2018.05.119_b0390","series-title":"Adverse effects of vaccines: evidence and causality. Influenza vaccine","author":"Institute of Medicine","year":"2012"},{"key":"10.1016\/j.vaccine.2018.05.119_b0395","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","article-title":"Association between Guillain-Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis","volume":"381","author":"Salmon","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.119_b0400","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2012.7342","article-title":"Risk of Guillain-Barr\u00e9 syndrome following H1N1 influenza vaccination in Quebec","volume":"308","author":"De Wals","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.05.119_b0405","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d3908","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe","volume":"343","author":"Dieleman","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.05.119_b0410","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barr\u00e9 Syndrome following Influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.119_b0415","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1016\/j.vaccine.2017.03.087","article-title":"Near real-time surveillance for Guillain-Barr\u00e9 syndrome after influenza vaccination among the Medicare population, 2010\/11 to 2013\/14","volume":"35","author":"Sandhu","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.119_b0420","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.05.119_b0425","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2105\/AJPH.2013.301651","article-title":"Cumulative risk of Guillain-Barr\u00e9 syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic","volume":"104","author":"Vellozzi","year":"2014","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2018.05.119_b0430","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(13)70104-X","article-title":"Risk of Guillain-Barr\u00e9 syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study","volume":"13","author":"Kwong","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2018.05.119_b0435","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/1469-0691.12447","article-title":"Barriers to the vaccination of children and adolescents and possible solutions","volume":"20","author":"Esposito","year":"2014","journal-title":"Clin Microbiol Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T14:59:29Z","timestamp":1566485969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18307989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":87,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X18307989"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.119","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine-preventable diseases, vaccines and Guillain-Barre\u2019 syndrome","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}